FTC Objections To Pharma Mergers Could Go Unchallenged Following Wilson’s Resignation
The commission no longer has a voice opposing aggressive antitrust enforcement actions and President Biden's replacement may be more receptive to the stance of the three current Democratic commissioners. Amgen’s proposed acquisition of Horizon is facing FTC scrutiny.
You may also be interested in...
Amgen To Enhance Rare Disease Franchise With $27.8bn Horizon Takeover
The US major has announced its biggest acquisition to date in the form of a takeover that should expand its rare disease franchise and stave off concerns about internal products facing biosimilar competition.
Indivior Looks To Cement Addiction Drug Leadership With Opiant Buy
Some observers believe Indivior is paying a very reasonable price to get hold of OPNT003, an intranasal formulation of the opioid antagonist nalmefene, which is expected to be filed with the US FDA by the end of the year.
FTC May Go After Pharma Bundling, Rebates, Patent Processes With Reactivation of Section 5
Agency restores long dormant enforcement of section of FTC Act prohibiting businesses from using ‘unfair methods of competition,’ expanding types of corporate behavior subject to enforcement action.